Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Oct 4 - Oct 9
For adults with established CV disease and a BMI 27 kg/m to reduce the chances of heart attack (non-fatal myocardial infarction)
Passage Bio Founded: 2017 Technology / disease area: One-time AAV-based gene therapy for rare and neurodegenerative disorders Lead candidate: PBFT02 Passage Bio is advancing one-time AAV gene therapies targeting the underlying causes of neurodegenerative diseases
A 300 L aliquot of the supernatant was transferred to an LC-MS injection vial and evaporated to dryness
2017;66:A321
US$ 21.24
US$ 26.47
US$ 20.72
